Internal Medicine, Pulmonary Disease · Las Vegas, NV
NPI
1790721116
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2000 Wellness Way
Las Vegas, NV, 89106
Phone (702) 384-5101
Groups this clinician bills Medicare through
Medicare paid, 2024
$82K
1,571 services
Medicare patients, 2024
387
Average age 73
Drug cost, 2024
$7.6M
3,479 prescriptions
Company payments, 2025
$12K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Naresh P Singh was code 99232 (hospital e&m - subsequent), 611 times for 225 patients. In total Naresh P Singh billed 1,571 services in 23 codes, and Medicare paid $82K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-11-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 611 | 225 | $58.59 | $36K |
| 99213 Office E&M - Established | Office | 103 | 76 | $58.91 | $6,068 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 100 | 74 | $11.90 | $1,190 |
| 99458 E&M - Miscellaneous | Office | 96 | 12 | $30.10 | $2,890 |
| 99222 Hospital E&M - Initial | Facility | 89 | 85 | $95.58 | $8,506 |
| 99457 E&M - Miscellaneous | Office | 89 | 13 | $37.51 | $3,339 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 79 | 13 | $36.73 | $2,902 |
| 99454 E&M - Miscellaneous | Office | 74 | 12 | $36.43 | $2,696 |
| 99214 Office E&M - Established | Office | 72 | 58 | $84.17 | $6,060 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 64 | 14 | $47.15 | $3,018 |
| 99212 Office E&M - Established | Office | 61 | 51 | $38.14 | $2,327 |
| 94010 Pulmonary Function Testing | Office | 40 | 34 | $19.45 | $778 |
| 99233 Hospital E&M - Subsequent | Facility | 25 | 14 | $89.14 | $2,229 |
| 99223 Hospital E&M - Initial | Facility | 21 | 21 | $124.63 | $2,617 |
| 94618 Pulmonary Function Testing | Office | 19 | 19 | $21.97 | $417 |
By year: 2022 $144K for 2,245 services; 2023 $126K for 1,891 services; 2024 $82K for 1,571 services.
Medicare prescription drug claims, 2024
In 2024, the drug Naresh P Singh prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 441 prescriptions and refills. In total Naresh P Singh wrote 3,479 Medicare prescriptions that cost $7.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 441 | 523 | 147 | $12K |
| Prednisone Generic | 334 | 422 | 95 | $1,368 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 267 | 375 | 60 | $240K |
| Montelukast Sodium Generic | 201 | 472 | 61 | $1,584 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 174 | 250 | 48 | $158K |
| Opsumit Macitentan | 147 | 147 | 16 | $1.8M |
| Ofev Nintedanib Esylate | 131 | 131 | 16 | $1.8M |
| Prolastin C Alpha-1-Proteinase Inhibitor | 114 | 116 | 11 | $1.3M |
| Breo Ellipta Fluticasone/Vilanterol | 98 | 131 | 23 | $51K |
| Azithromycin Generic | 91 | 91 | 34 | $505 |
| Spiriva Respimat Tiotropium Bromide | 87 | 119 | 22 | $62K |
| Cefuroxime Cefuroxime Axetil | 74 | 74 | 27 | $658 |
| Ventolin Hfa Albuterol Sulfate | 73 | 86 | 22 | $5,652 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 73 | 114 | 19 | $11K |
| Symbicort Budesonide/Formoterol Fumarate | 67 | 131 | 27 | $30K |
Brand drugs: 1,801 claims; generic drugs: 1,678 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Naresh P Singh $12K ($12K in general payments such as food, travel and fees) from 11 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $8,369.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 12 | $8,369 |
| Grifols USA, LLC | 3 | $2,274 |
| Actelion Pharmaceuticals US, Inc. JNJ | 7 | $253 |
| United Therapeutics Corporation UTHR | 2 | $224 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $208 |
| Merck Sharp & Dohme LLC MRK | 3 | $147 |
| Verona Pharma, Inc. VRNA | 1 | $51.95 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $16.15 |
| GlaxoSmithKline, LLC. GSK | 1 | $15.65 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.